Profile data is unavailable for this security.
About the company
Nkarta, Inc. is a clinical-stage biopharmaceutical company advancing the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is developing NKX019, a chimeric antigen receptor-natural killer (CAR NK) product candidate targeting the CD19 antigen for the treatment of patients with autoimmune diseases and NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands. NKX019 is engineered with a humanized CD19-directed CAR for enhanced cell targeting and a proprietary, membrane-bound form of interleukin-15 (IL-15) for greater persistence and activity without exogenous cytokine support. CD19 is a biomarker for normal B cells as well as those implicated in autoimmune disease and B cell-derived malignancies. Its NKX019 autoimmune program is based on the potential to eliminate the pathologic B cells that produce autoantibodies.
- Revenue in USD (TTM)0.00
- Net income in USD-102.61m
- Incorporated2015
- Employees105.00
- LocationNkarta Inc1150 Veterans BoulevardSOUTH SAN FRANCISCO 94080United StatesUSA
- Phone+1 (925) 407-1049
- Fax+1 (302) 655-5049
- Websitehttps://www.nkartatx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Microbot Medical Inc | 0.00 | -13.07m | 134.32m | 21.00 | -- | 1.68 | -- | -- | -0.4513 | -0.4513 | 0.00 | 1.19 | 0.00 | -- | -- | 0.00 | -30.06 | -67.69 | -31.62 | -80.15 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -6.55 | -- | -35.03 | -- |
| Unicycive Therapeutics Inc | 0.00 | -33.47m | 134.32m | 22.00 | -- | 3.48 | -- | -- | -2.85 | -2.85 | 0.00 | 1.80 | 0.00 | -- | -- | 0.00 | -74.93 | -188.44 | -101.88 | -723.53 | -- | -- | -- | -6,003.20 | -- | -- | 0.00 | -- | -100.00 | -- | -20.42 | -- | -- | -- |
| ALX Oncology Holdings Inc | 0.00 | -108.01m | 134.46m | 44.00 | -- | 2.97 | -- | -- | -2.01 | -2.01 | 0.00 | 0.8362 | 0.00 | -- | -- | 0.00 | -80.47 | -37.96 | -103.67 | -40.71 | -- | -- | -- | -46,390.86 | -- | -- | 0.2099 | -- | -- | -- | 16.14 | -- | 4.84 | -- |
| Fate Therapeutics Inc | 7.14m | -156.09m | 134.96m | 181.00 | -- | 0.5765 | -- | 18.91 | -1.32 | -1.32 | 0.0603 | 2.03 | 0.017 | -- | 2.30 | 39,430.94 | -37.23 | -32.44 | -40.38 | -36.57 | -- | -- | -2,187.11 | -389.06 | -- | -- | 0.00 | -- | -78.55 | 5.00 | -15.74 | -- | -37.07 | -- |
| vTv Therapeutics Inc | 17.00k | -23.47m | 135.44m | 23.00 | -- | 1.92 | -- | 7,966.87 | -3.32 | -3.32 | 0.0024 | 17.91 | 0.0002 | -- | -- | 739.13 | -39.79 | -96.30 | -46.08 | -- | -- | -- | -166,935.30 | -775.06 | -- | -- | 0.0046 | -- | -- | -18.12 | 8.83 | -- | -- | -- |
| Vaxart Inc | 148.20m | -50.70m | 137.97m | 105.00 | -- | 4.92 | -- | 0.9309 | -0.2222 | -0.2222 | 0.6495 | 0.1169 | 0.789 | -- | 3.31 | 1,411,467.00 | -26.99 | -49.90 | -80.48 | -58.33 | -- | -- | -34.21 | -875.06 | -- | -31.43 | 0.1161 | -- | 288.94 | 23.82 | 18.82 | -- | -8.21 | -- |
| HST Global Inc | 0.00 | -212.63k | 139.70m | 1.00 | -- | 8.48 | -- | -- | -0.0107 | -0.0107 | 0.00 | 0.1167 | 0.00 | -- | -- | -- | -6.87 | -27.80 | -8.09 | -60.19 | -- | -- | -- | -- | -- | -107.48 | 0.0433 | -- | -- | -- | -45.42 | -- | -- | -- |
| Sangamo Therapeutics Inc | 32.88m | -108.91m | 139.77m | 183.00 | -- | 20.18 | -- | 4.25 | -0.4428 | -0.4428 | 0.1326 | 0.0194 | 0.3289 | -- | 5.97 | 179,644.80 | -108.96 | -30.73 | -204.29 | -37.33 | -- | -- | -331.28 | -147.59 | -- | -- | 0.00 | -- | -67.20 | -10.81 | 62.01 | -- | -58.10 | -- |
| Nkarta Inc | 0.00 | -102.61m | 142.06m | 105.00 | -- | 0.4204 | -- | -- | -1.39 | -1.39 | 0.00 | 4.76 | 0.00 | -- | -- | 0.00 | -21.39 | -29.78 | -22.36 | -31.23 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 7.41 | -- | 17.99 | -- |
| Tenaya Therapeutics Inc | 0.00 | -94.26m | 145.28m | 97.00 | -- | 1.34 | -- | -- | -0.7875 | -0.7875 | 0.00 | 0.5061 | 0.00 | -- | -- | 0.00 | -76.77 | -47.44 | -87.21 | -51.82 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 10.44 | -- | -18.92 | -- |
| Angion Biomedica Corp | 0.00 | -45.86m | 146.91m | 32.00 | -- | 37.99 | -- | -- | -3.15 | -3.15 | 0.00 | 0.2211 | 0.00 | -- | -- | 0.00 | -137.56 | -106.87 | -179.35 | -289.86 | -- | -- | -- | -778.01 | -- | -302.49 | 0.7181 | -- | -- | -- | -47.46 | -- | -18.50 | -- |
| Caribou Biosciences Inc | 9.30m | -157.13m | 148.61m | 147.00 | -- | 1.05 | -- | 15.99 | -1.70 | -1.70 | 0.1004 | 1.52 | 0.0345 | -- | 6.57 | 63,231.29 | -58.27 | -30.69 | -65.59 | -33.30 | -- | -- | -1,690.45 | -562.81 | -- | -- | 0.00 | -- | -71.01 | 11.54 | -46.08 | -- | 40.73 | -- |
| ProQR Therapeutics NV | 19.08m | -50.53m | 149.59m | 166.00 | -- | 2.26 | -- | 7.84 | -0.486 | -0.486 | 0.1837 | 0.6289 | 0.139 | -- | 9.70 | 114,938.80 | -36.82 | -29.87 | -53.74 | -35.27 | -- | -- | -264.83 | -501.81 | -- | -- | 0.2242 | -- | 105.20 | 58.84 | 1.27 | -- | 19.58 | -- |
| Connect Biopharma Holdings Ltd (ADR) | 762.00k | -50.77m | 149.82m | 62.00 | -- | 2.70 | -- | 196.62 | -0.9144 | -0.9144 | 0.0137 | 0.9926 | -- | -- | -- | 12,290.32 | -- | -61.12 | -- | -66.78 | -- | -- | -6,662.99 | -1,963.00 | -- | -- | 0.00 | -- | -- | -- | 74.84 | -- | 37.04 | -- |
Data as of Feb 12 2026. Currency figures normalised to Nkarta Inc's reporting currency: US Dollar USD
47.52%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| RA Capital Management LPas of 30 Sep 2025 | 10.81m | 15.21% |
| Tang Capital Management LLCas of 30 Sep 2025 | 7.06m | 9.93% |
| BlackRock Fund Advisorsas of 30 Sep 2025 | 3.21m | 4.52% |
| Citadel Advisors LLCas of 30 Sep 2025 | 2.44m | 3.44% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 2.25m | 3.17% |
| Alyeska Investment Group LPas of 30 Sep 2025 | 2.08m | 2.94% |
| Monaco Asset Management SAMas of 30 Sep 2025 | 1.97m | 2.78% |
| Wasatch Advisors LPas of 30 Sep 2025 | 1.64m | 2.31% |
| SSgA Funds Management, Inc.as of 30 Sep 2025 | 1.15m | 1.62% |
| Renaissance Technologies LLCas of 30 Sep 2025 | 1.15m | 1.61% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
